Stock listing
OTC:GRTX Galera Therapeutics, Inc. Stock
Follow Galera Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:GRTX
$12.00 USD -0.15 (-1.2%)
Close on Nov 20, 2026 · Data provided by Twelve Data
- Day range
- $11.76 – $12.30 USDNov 20, 2026
- Volume
- 336,160 sharesNov 20, 2026
- Market cap
- —Left out: price × shares is far from the company's reported size
- 52-week range
- $4.02 – $50.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.80M USDMedian day 377,921 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:GRTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.00 | -0.15 | -1.2% | $12.01 | $12.30 | $11.76 | 336,160 | |
| $12.15 | -0.06 | -0.5% | $12.30 | $12.81 | $11.99 | 361,890 | |
| $12.21 | +0.14 | +1.2% | $12.00 | $13.25 | $11.73 | 681,210 | |
| $12.07 | -0.29 | -2.3% | $12.26 | $12.51 | $11.88 | 282,022 | |
| $12.36 | -0.20 | -1.6% | $12.50 | $12.71 | $11.85 | 727,866 | |
| $12.56 | +0.08 | +0.6% | $12.37 | $13.00 | $11.80 | 314,042 | |
| $12.48 | -0.40 | -3.1% | $12.99 | $13.04 | $12.00 | 328,742 | |
| $12.88 | -0.86 | -6.3% | $13.77 | $14.00 | $12.82 | 663,428 | |
| $13.74 | +0.03 | +0.2% | $13.39 | $14.03 | $12.74 | 744,000 | |
| $13.71 | -0.155 | -1.1% | $13.34 | $14.21 | $12.40 | 1,143,735 | |
| $13.87 | +4.265 | +44.4% | $10.41 | $14.77 | $9.71 | 2,092,191 | |
| $9.60 | -1.39 | -12.6% | $10.98 | $10.98 | $9.60 | 778,314 | |
| $10.99 | -2.24 | -16.9% | $13.55 | $13.75 | $10.60 | 544,019 | |
| $13.23 | -1.20 | -8.3% | $14.23 | $14.97 | $13.01 | 626,849 | |
| $14.43 | -0.36 | -2.4% | $14.62 | $14.92 | $13.48 | 526,048 | |
| $14.79 | +0.27 | +1.9% | $14.55 | $15.52 | $13.66 | 563,091 | |
| $14.52 | -0.07 | -0.5% | $14.67 | $15.87 | $14.30 | 248,152 | |
| $14.59 | +0.34 | +2.4% | $13.38 | $15.00 | $13.38 | 411,962 | |
| $14.25 | +0.39 | +2.8% | $13.72 | $14.31 | $13.20 | 397,721 | |
| $13.86 | -0.12 | -0.9% | $14.07 | $14.30 | $13.16 | 204,801 | |
| $13.98 | +0.04 | +0.3% | $13.83 | $14.17 | $13.43 | 279,756 | |
| $13.94 | +0.01 | +0.1% | $14.10 | $14.50 | $13.74 | 174,494 | |
| $13.93 | +0.68 | +5.1% | $13.34 | $14.60 | $13.34 | 332,844 | |
| $13.25 | +1.31 | +11.0% | $11.97 | $13.47 | $11.57 | 410,945 | |
| $11.94 | +0.17 | +1.4% | $11.75 | $12.00 | $11.52 | 106,444 | |
| $11.77 | -0.43 | -3.5% | $12.31 | $12.46 | $11.62 | 297,719 | |
| $12.20 | -0.02 | -0.2% | $12.31 | $12.67 | $12.06 | 240,337 | |
| $12.22 | +0.23 | +1.9% | $12.00 | $12.67 | $11.79 | 298,258 | |
| $11.99 | -0.80 | -6.3% | $12.96 | $13.18 | $11.86 | 377,259 | |
| $12.79 | -0.21 | -1.6% | $13.13 | $13.21 | $12.61 | 420,010 | |
| $13.00 | +0.76 | +6.2% | $12.25 | $13.95 | $12.25 | 532,207 | |
| $12.24 | -0.96 | -7.3% | $13.14 | $13.39 | $12.07 | 517,206 | |
| $13.20 | -0.02 | -0.2% | $13.02 | $13.88 | $12.80 | 359,041 | |
| $13.22 | -0.62 | -4.5% | $13.84 | $14.42 | $13.00 | 288,797 | |
| $13.84 | +0.25 | +1.8% | $13.45 | $14.26 | $13.09 | 199,185 | |
| $13.59 | +0.27 | +2.0% | $13.07 | $13.90 | $13.07 | 228,988 | |
| $13.32 | -0.41 | -3.0% | $13.86 | $14.68 | $13.16 | 299,804 | |
| $13.73 | -0.85 | -5.8% | $14.58 | $14.70 | $13.11 | 351,595 | |
| $14.58 | +1.21 | +9.1% | $13.28 | $15.38 | $12.80 | 378,583 | |
| $13.37 | +0.51 | +4.0% | $12.91 | $13.73 | $12.33 | 912,961 | |
| $12.86 | -0.55 | -4.1% | $13.54 | $13.70 | $12.16 | 454,560 | |
| $13.41 | -1.85 | -12.1% | $15.27 | $15.66 | $13.20 | 426,630 | |
| $15.26 | -1.74 | -10.2% | $17.10 | $17.10 | $15.25 | 582,606 | |
| $17.00 | -0.33 | -1.9% | $17.44 | $17.97 | $16.71 | 1,151,577 | |
| $17.33 | -0.42 | -2.4% | $18.08 | $18.21 | $17.14 | 1,104,889 | |
| $17.75 | +0.25 | +1.4% | $17.61 | $18.16 | $17.36 | 3,974,351 | |
| $17.50 | +0.35 | +2.0% | $17.16 | $18.19 | $17.16 | 829,641 | |
| $17.15 | +0.15 | +0.9% | $17.29 | $18.10 | $16.91 | 1,167,024 | |
| $17.00 | -1.10 | -6.1% | $18.17 | $18.75 | $17.00 | 472,267 | |
| $18.10 | +0.30 | +1.7% | $18.39 | $19.00 | $17.84 | 455,457 | |
| $17.80 | +0.64 | +3.7% | $17.23 | $18.49 | $17.17 | 392,799 | |
| $17.16 | -1.52 | -8.1% | $18.65 | $19.55 | $17.00 | 454,209 | |
| $18.68 | -0.05 | -0.3% | $18.16 | $19.97 | $18.16 | 332,204 | |
| $18.73 | +1.91 | +11.4% | $16.98 | $19.87 | $16.98 | 599,438 | |
| $16.82 | -0.27 | -1.6% | $17.26 | $19.00 | $16.57 | 140,120 | |
| $17.09 | +0.09 | +0.5% | $16.85 | $18.06 | $16.15 | 136,232 | |
| $17.00 | -0.04 | -0.2% | $17.35 | $18.01 | $16.25 | 126,347 | |
| $17.04 | -0.47 | -2.7% | $17.18 | $18.09 | $16.27 | 79,263 | |
| $17.51 | +1.21 | +7.4% | $16.55 | $17.99 | $15.53 | 142,522 | |
| $16.30 | -0.74 | -4.3% | $16.58 | $18.11 | $15.85 | 260,571 | |
| $17.04 | -1.36 | -7.4% | $17.80 | $18.72 | $16.80 | 65,063 | |
| $18.40 | -0.60 | -3.2% | $18.32 | $19.20 | $17.79 | 118,409 | |
| $19.00 | +0.30 | +1.6% | $19.29 | $19.44 | $18.50 | 155,712 | |
| $18.70 | -1.20 | -6.0% | $20.39 | $21.98 | $17.80 | 133,102 | |
| $19.90 | -0.29 | -1.4% | $20.47 | $21.33 | $18.44 | 1,449,276 | |
| $20.19 | +0.19 | +1.0% | $20.20 | $21.03 | $19.70 | 74,359 |
- Ticker
- OTC:GRTX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Apr 14, 2026
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Latest deck · Jun 2, 2026
Merger or Acquisition (June 2026)
Merger or acquisition · 19 slides
Latest news
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Apr 14, 2026
Closed $15.78 (+87.9%) on Apr 14, 2026
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Apr 14, 2026
Closed $15.78 (+87.9%) on Apr 14, 2026
Galera Therapeutics, Inc. on 6ix
- News releases
- 2 in the last 12 months · 4 in all · newest Apr 14, 2026 · oldest 2025
- Decks
- 13 decks · latest Jun 2, 2026
Valuation
price Nov 20, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.79
Team and board
| Officer | Role |
|---|---|
| Caroline Code | VP Corporate Development & Investor Relations |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (June 2026) | Merger or acquisition | 19 slides | Jun 2, 2026 |
| Merger or Acquisition (April 2026) | Merger or acquisition | 17 slides | Apr 14, 2026 |
| Investor Presentation (December 2024) | Investor deck | 35 slides | Dec 31, 2024 |
| Investor Presentation (October 2022) | Investor deck | 48 slides | Oct 26, 2022 |
| Technical Presentation (December 2021) | Technical | 18 slides | Dec 14, 2021 |
| Investor Presentation (September 2021) | Investor deck | 50 slides | Sep 8, 2021 |
| Investor Presentation (April 2021) | Investor deck | 44 slides | Apr 28, 2021 |
| Investor Presentation (January 2021) | Investor deck | 47 slides | Jan 6, 2021 |
| Investor Presentation (November 2020) | Investor deck | 41 slides | Nov 10, 2020 |
| Investor Presentation (September 2020) | Investor deck | 32 slides | Sep 16, 2020 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2020) | Investor deck | 29 slides | Sep 9, 2020 |
| Investor Presentation (July 2020) | Investor deck | 29 slides | Jul 14, 2020 |
| Investor Presentation (May 2020) | Investor deck | 33 slides | May 12, 2020 |
Financings
| Raise | Date |
|---|---|
| Private placement of private placement financing Announced: US$350M · Leerink Partners +4 Dealers: Leerink Partners, TD Cowen, Piper Sandler, William Blair, LifeSci Capital Buyers: Balyasny Asset Management; Caligan Partners LP; Eventide Asset Management; Nantahala Capital; Octagon Capital; Redmile; Spruce Street Capital; Trails Edge Capital Partners; Atlas Venture; Deep Track Capital; Foresite Capital; Janus Henderson Investors Use of proceeds: Fund the combined company into the second half of 2028 and through clinical milestones for OBX-115, including NSCLC Phase 1 data and melanoma registration-enabling data | Apr 14, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Cap table
Built by 6ix from Galera Therapeutics, Inc.’s releases · as of Apr 14, 2026
- Common shares
- 377,311
- Fully diluted
- 377,311
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 377,311 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 377,311 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lawrence M. Alleva Other companies: Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Adaptimmune Therapeutics PLC (Chairman and Non-Executive Director · Since at least Jan 1, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past) | Director · Since at least Nov 6, 2019 |
| Michael Powell Other companies: Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Checkmate Pharmaceuticals Inc (Director · Aug 6, 2020 – May 31, 2022 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 5, 2019 · Past) | Director · Nov 6, 2019 – Jun 14, 2023 · Past |
| Caroline Code Other companies: Obsidian Therapeutics, Inc. (VP Corporate Development and Investor Relations · Since at least Aug 5, 2026) | VP Corporate Development & Investor Relations · Since at least Apr 14, 2026 |
| Eugene P Kennedy Other companies: Lumos Pharma Inc (Chief Medical Officer · Nov 13, 2017 – Feb 1, 2021 · Past) | Chief Medical Officer · Sep 1, 2022 – Feb 25, 2023 · Past |
| Mark J. Bachleda Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 9, 2025) | Chief Commercial Officer · Oct 8, 2021 – Mar 16, 2023 · Past |
| Robert Beardsley Other companies: Arbutus Biopharma Corporation (Director · Since at least Feb 24, 2025) | Chief Operating Officer · Nov 6, 2019 – Feb 25, 2023 · Past |
| Jason Fuller | Director · Nov 6, 2019 – Nov 6, 2019 · Past |
| Jon T Holmlund | Chief Medical Officer · Nov 6, 2019 – Feb 28, 2022 · Past |
| Mel Sorensen | President and CEO, Director · Since at least Nov 6, 2019 |
| Michael R Friedman | Director · Since at least Dec 30, 2024 |
Log in to ask 6ix AI your own questions about Galera Therapeutics, Inc.